Table 5 Comparison among chemoradiotherapy studies, using nedaplatin/5-FU for esophageal cancer

Inaba H

[37]

10

60

200/body

10,000/body

I--IVB

80

50

80 (1 y)

90

Osawa S *

33

50.4--66

200/body

10,000/body

I--IVB

90.9

60.6

83 (1 y)

77 (2 y)

75.8

B. Intermittent standard-dose nedaplatin and 5-FU regimens

Author

No.

Radiation

(Gy)

Total dose (mg)

Nedaplatin

5FU

Stage

RR

(%)

CR

(%)

Survival rate (%)

Leucopenia (%)

Kato H

[38]

22

60--66

160/m²

5,000/m²

I--IV

77

9

30.7 (1 y)

10.2 (2 y)

15.4

17

40

80/m²

25,000/m²

pre-S

II--IV

70.6

28.6

48.2 (1 y)

12.1 (2 y)

Yamanaka H

[39]

17

40

200/body

14,000/body

I--IVB

76.5

11.8

52.9 (1 y)

17.6

Nemoto K

[40]

17

60--70

200/body

15,000/body

I--IVA

94.1

41.2

59 (1 y)

39 (2 y)

25

7

60--70

200/body

15,000/body

post-S

recur

100

0

69 (1 y)

69 (2 y)

Ishikura S

[14]

26

60

180/m²

8,000/m²

III--IVB

---

12

50 (1 y)

31 (2 y)

35

Sato Y

[12]

26

60

100/m²

4,000/m²

I--IVA

88.5

42.3

65.1 (1 y)

37.2 (3 y)

40

Kodaira T

[13]

40

60

360/m²

10,500/m²

III--IV

76

48

58.9 (1 y)

45.9 (2 y)

80

Yamashita H

[41]

12

50.4

160/m²

6,400/m²

II--IVB

82

73

40 (1 y)

13 (2 y)

50

Jingu K

[42]

30

60

140/m²

5,000/m²

post-S

recur

73.3

13.3

60.6 (1 y)

56.3 (3 y)

30